Document is current
Any future updates will be listed below
-
Authors
Chan, Jasper Fuk-Woo https://orcid.org/0000-0001-6336-6657
Yuan, Shuofeng https://orcid.org/0000-0001-7996-1119
Chu, Hin https://orcid.org/0000-0003-2855-9837
Sridhar, Siddharth https://orcid.org/0000-0002-2022-8307
Yuen, Kwok-Yung https://orcid.org/0000-0002-2083-1552
- License Information
-
More Information
Article History
Accepted: 28 February 2024
First Online: 15 April 2024
Competing interests
: J.F.-W.C. has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Ltd, and was an invited speaker for Gilead Sciences Hong Kong Ltd and Luminex Corporation. K.-Y.Y. is a shareholder of Hong Kong Universal Biologicals Company Ltd and Hong Kong Universal Vaccine Ltd, and collaborates with Sinovac Biotech Ltd and China National Pharmaceutical Group Co., Ltd (Sinopharm). J.F.-W.C., S.Y., H.C. and K.-Y.Y. have patent applications on a number of therapeutic candidates included in this article. S.S. declares no competing interests.
